Budget Reaction quote by Dr. Sabine Kapasi, Global Health Strategist, UN advisor & Founder of ROPAN Healthcare Private Ltd

“The Budget’s Biopharma Shakti programme with a ₹10,000 crore outlay is a forward-looking move that recognises both India’s growing non-communicable disease burden and the importance of biologic medicines in improving longevity and quality of life at affordable costs. Expanding NIPER capacity, building a nationwide clinical trials network, and strengthening the drug regulatory system can significantly accelerate research, approvals, and domestic manufacturing of biologics and biosimilars. The additional focus on evidence-based traditional medicine, including three new All India Institutes of Ayurveda, upgrades to Ayush pharmacies and drug testing labs, and strengthening the WHO Global Traditional Medicine Centre in Jamnagar, reflects a more integrated view of healthcare delivery and research. Along with medical tourism hubs and expanded veterinary and paraveterinary infrastructure, this signals a broader ecosystem approach to health and life sciences. If implemented well, these measures can improve access, build global credibility, and position India as a serious innovation and manufacturing hub across healthcare segments.”